Thomas R O'brien

List of Publications by Year
in descending order

45 papers	2,497 citations	471509 17 h-index	243625 44 g-index
46 all docs	46 docs citations	46 times ranked	3963 citing authors

#	Article	IF	Citations
1	Declining US Hepatocellular Carcinoma Rates, 2014â€“2017. Clinical Gastroenterology and Hepatology, 2022, 20, e330-e334.	4.4	9
2	The role of IFNL4 in liver inflammation and progression of fibrosis. Genes and Immunity, 2022, 23, 111-117.	4.1	2
3	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Journal of Infectious Diseases, 2021, 223, 2090-2098.	4.0	5
4	Death certificates compared to SEERâ€Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection. Journal of Viral Hepatitis, 2021, 28, 934-941.	2.0	3
5	Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virusâ€and hepatitis C virusâ€infected individuals. Alimentary Pharmacology and Therapeutics, 2021, 54, 833-842.	3.7	14
6	Intracellular Accumulation of IFN-Î»4 Induces ER Stress and Results in Anti-Cirrhotic but Pro-HCV Effects. Frontiers in Immunology, 2021, 12, 692263.	4.8	6
7	Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. Scientific Reports, 2021, 11, 21194.	3.3	5
8	The Impact of IFNÎ»4 on the Adaptive Immune Response to SARS-CoV-2 Infection. Journal of Interferon and Cytokine Research, 2021, 41, 407-414.	1.2	3
9	Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-Î”G and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. Journal of Infectious Diseases, 2020, 221, 102-109.	4.0	6
10	IFNL4: Notable variants and associated phenotypes,. Gene, 2020, 730, 144289.	2.2	14
11	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes and Immunity, 2020, 21, 348-359.	4.1	5
12	COVID-19 and emerging viral infections: The case for interferon lambda. Journal of Experimental Medicine, 2020, 217, .	8.5	177
13	Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma. Journal of Hepatology, 2020, 73, 1583-1584.	3.7	1
14	Prediagnostic serum polychlorinated biphenyl concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. Environmental Research, 2020, 187, 109690.	7.5	10
15	Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: Whatâ€™s the Score?. Hepatology, 2020, 72, 794-796.	7.3	7
16	Recent Decline in Hepatocellular Carcinoma Rates in the United States. Gastroenterology, 2020, 158, 1503-1505.e2.	1.3	36
17	Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-Î» to Treat Early Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 1410-1412.	5.8	88
18	CCR5-Î”32 and IFNL4-Î”G/TT. Clinical Therapeutics, 2019, 41, 2658-2659.	2.5	0

#	Article	IF	Citations
19	Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. Journal of Viral Hepatitis, 2019, 26, 738-749.	2.0	20
20	Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A caseâ€“control study nested within two prospective cohorts. International Journal of Cancer, 2019, 145, 2360-2371.	5.1	14
21	What Have We Learned from Studies of IFN-Î» Variants and Hepatitis C Virus Infection?. Journal of Interferon and Cytokine Research, 2019, 39, 618-626.	1.2	3
22	Meeting Overview: Interferon Lambdaâ€"Disease Impact and Therapeutic Potential. Journal of Interferon and Cytokine Research, 2019, 39, 586-591.	1.2	5
23	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology, 2019, 156, 1496-1507.e7.	1.3	32
24	Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer, 2019, 125, 2621-2630.	4.1	24
25	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology, 2019, 156, 400-417.	1.3	35
26	What makes the hepatitis C virus evolve?. ELife, 2019, 8, .	6.0	1
27	Beasleyâ€™s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. Cancer Epidemiology, 2018, 53, 195-199.	1.9	5
28	Hepatitis D Viremia Among Injection Drug Users in San Francisco. Journal of Infectious Diseases, 2018, 217, 1902-1906.	4.0	24
29	Impact of IFNL4 -âˆ†G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals. Diagnostic Microbiology and Infectious Disease, 2018, 92, 34-36.	1.8	4
30	Race or genetic makeup for hepatitis C virus treatment decisions?. Hepatology, 2017, 65, 2124-2125.	7.3	18
31	Shortening the duration of therapy for chronic hepatitis C infection. The Lancet Gastroenterology and Hepatology, 2017, 2, 832-836.	8.1	35
32	IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir. Gastroenterology, 2017, 153, 1694-1695.	1.3	19
33	Relationship of Genotype for HLA B*57 and IFNL4 With Disease Progression in Female HIV Controllers. Clinical Infectious Diseases, 2017, 65, 1243-1244.	5.8	3
34	No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL. Hepatology, 2016, 63, 28-30.	7.3	32
35	Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. PLoS ONE, 2016, 11, e0166036.	2.5	9
36	Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. PLoS ONE, 2015, 10, e0138827.	2.5	6

#	Article	IF	Citations
37	Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. Journal of Hepatology, 2015, 63, 1103-1110.	3.7	61
38	IFN-Î»4: The Paradoxical New Member of the Interferon Lambda Family. Journal of Interferon and Cytokine Research, 2014, 34, 829-838.	1.2	130
39	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genetics, 2013, 45, 164-171.	21.4	843
40	An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C. PLoS ONE, 2011, 6, e20904.	2.5	25
41	Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2004, 10, 67-73.	2.0	12
42	Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression. Immunogenetics, 2003, 55, 157-164.	2.4	15
43	Genetic effects on HIV disease progression. Nature Medicine, 1998, 4, 536-536.	30.7	49
44	Relative resistance to HIVâ€“1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple highâ€“risk sexual exposures. Nature Medicine, 1996, 2, 412-417.	30.7	676
45	Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. American Journal of Hematology, 1995, 49, 201-206.	4.1	6